CAII-IN-15
CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with a hCA II IC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma.
For research use only. We do not sell to patients.
- Formula: C14H13N3O6S
- Molecular Weight:351.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
hCA II 10 nM (IC50) |
hCA IX 32 nM (IC50) |
hCA I 430 nM (IC50) |
hCA XII 19 nM (IC50) |
NLRP3 inflammasome |
In Vitro
CAII-IN-15 (compound B6) (0.5 nM-5 mM; 15 min) potently and selectively inhibits recombinant human CA II with an IC50 of 10 nM, and demonstrates moderate inhibition of hCA I (IC50 = 430 nM), hCA IX (IC50 = 32 nM), and hCA XII (IC50 = 19 nM)[1].
CAII-IN-15 binds to the active site of CA II via Zn2+ coordination, hydrogen bonding with THR199 and GLN92, and π-π stacking with PHE131, supporting its potent inhibitory activity[1].
CAII-IN-15 (10 μM; 24 h) elevates cGMP levels in human trabecular meshwork (HTM) cells, confirming activation of the NO/sGC/cGMP signaling pathway[1].
CAII-IN-15 (5-20 μM; 4 h) provides concentration-dependent neuroprotection against oxygen-glucose deprivation (OGD)-induced injury in SH-SY5Y cells[1].
CAII-IN-15 (10 μM; 24 h) inhibits LPS (HY-D1056)-induced increase in IL-1β and NLRP3 inflammasome in Müller cells [1].
CAII-IN-15 (10 μM; 4 h) suppresses OGD/R-induced ROS elevation in retinal precursor R28 cells[1].
CAII-IN-15 (0.032-100 μM; 24 h) exhibits dose-dependent cytotoxicity across multiple ocular cell types[1].
CAII-IN-15 (1.56-50.00 μg/mL; 1 h) shows no significant hemolytic activity against rabbit erythrocytes at concentrations from 1.56 μg/mL to 50.00 μg/mL, with hemolysis rates consistently below 5%, demonstrating excellent blood compatibility[1].
CAII-IN-15 (0-30 μM) does not significantly inhibit the hERG potassium channel at concentrations up to 30 μM, indicating a low risk of arrhythmias and favorable cardiac safety[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human trabecular meshwork (HTM) cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly Increased intracellular cGMP levels to approximately 15.8 nmol/L.
-
Cell Line:SH-SY5Y cells
-
Concentration:5; 10; 20 μM
-
Incubation Time:4 h
-
Result:Restored OGD-reduced cell viability to 88.10% (5 μM), 91.12% (10 μM), and 93.71% (20 μM).
Showed concentration-dependent neuroprotection.
-
Cell Line:lipopolysaccharide (LPS)-stimulated Müller cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Substantially reduced LPS-induced ASC speck counts and IL-1β concentrations.
-
Cell Line:conjunctival cells, human corneal epithelial cells (HCEC), human trabecular meshwork cells (HTMC), lens B3 cells, retinal R28 cells, and 661W cells
-
Concentration:0.032; 0.16; 0.8; 4 μM (conjunctival cells); 0.8; 4; 20; 100 μM (HCEC, HTMC, B3, R28, 661W cells)
-
Incubation Time:24 h
-
Result:Decreased conjunctival cell viability from 97.76% to 76.76% across tested concentrations, with 15.09% higher viability than brinzolamide at 0.032 μM.
Decreased HCEC viability from 99.67% to 76.00%, with 5.33% higher viability than brinzolamide at 100 μM.
Decreased HTMC viability from 99.83% to 91.00%, with 3.73% higher viability than brinzolamide at 4 μM.
Decreased B3 cell viability from 99.67% to 90.33%, with 3.09% higher viability than brinzolamide at 4 μM.
Decreased R28 cell viability from 95.90% to 70.67%, with 7.10% higher viability than brinzolamide at 4 μM.
Decreased 661W cell viability from 91.71% to 75.97%, with 10.86% higher viability than brinzolamide at 4 μM.
In Vivo
CAII-IN-15 (1% carbomer suspension, 0.1 mL; topical (conjunctival sac instillation); single dose) exhibits minimal ocular irritation in rabbits[1].
CAII-IN-15 (100 μL 1% solution; topical (ocular instillation); single dose) releases nitric oxide in rabbit aqueous humor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg) bilateral intravitreally injected with 0.05 mL 5% hypertonic saline[1]
-
Dosage:0.05 mL in 1% carbomer suspension
-
Administration:topical (conjunctival sac instillation); single dose
-
Result:Achieved a maximum IOP reduction of -6.5 mmHg at 30 minutes post-administration.
Exhibited sustained efficacy lasting until 240 minutes.
-
Animal Model:Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg) bilateral intravitreally injected with with 0.1 mL Carbomer (HY-W250721D)[1]
-
Dosage:0.05 mL in1% carbomer suspension
-
Administration:topical (conjunctival sac instillation); twice daily; 28 days
-
Result:Provided consistent additional IOP reduction throughout the core observation period (days 10-26), with peak differences of 3.0 mmHg recorded on days 14 and 17.
-
Animal Model:Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg)[1]
-
Dosage:0.1 mL in 1% carbomer suspension
-
Administration:topical (conjunctival sac instillation); single dose
-
Result:At 1 hour post-instillation, showed mild conjunctival hyperemia and minimal secretion with a total irritation score of 0.75.
Scores returned to baseline (0) by 2 hours.
Classified as a non-irritant (maximum score ≤1).
-
Animal Model:Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg)[1]
-
Dosage:1% solution, 100 μL
-
Administration:topical (ocular instillation); single dose
-
Result:Released nitric oxide at a concentration of 5.75-6.21 μM at 0.5 hour post-administration.
Decreased Nitric oxide release sharply at 1 hour and 1.5 hours post-administration.
Chemical Information
-
Molecular Weight 351.33
-
Formula C14H13N3O6S
-
SMILES
O=C(NC1=CC=C(S(=O)(N)=O)C=C1)C2=CC=C(CO[N+]([O-])=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- CAII-IN-15
- Carbonic Anhydrase
- Apoptosis
- NOD-like Receptor (NLR)
- Interleukin Related
- Reactive Oxygen Species (ROS)
- CYP1A2
- human trabecular meshwork cells
- NLRP3 inflammasome
- SH-SY5Y cells
- Müller cells
- human CA II
- rabbit erythrocytes
- retinal precursor R28 cells
- carbonic anhydrase II
- hERG potassium channel
- Inhibitor
- inhibitor
- inhibit